G.D. ALEMANOVA, L.YU. POPOVA, E.A. ZLODEEVA, O.V. VOLYANIK, R.R. KASHAEVA

Orenburg State Medical University of the Ministry of Health of Russia, Orenburg

 Contact details:

Alemanova G.D. — MD, Associate Professor of the Department of Children’s Diseases

Address: 6 Sovetskaya St., Orenburg, Russian Federation, 460000, tel.: +7-922-847-72-03, e-mail: galina.alemanova@bk.ru

This article presents the results of anti-IgE-therapy in children with severe persistent uncontrolled atopic bronchial asthma. The clinical course of the disease during 3 years of follow-up was analyzed. The effectiveness of IgE-therapy was evaluated by the frequency of hospitalizations, asthma control, and changes in baseline therapy. Treatment with Omalizumab resulted in decreased frequency of acute states, normalized external respiration function, reduced severity of co-morbid pathology in the form of allergic rhinitis and atopic dermatitis.

Key words: children, bronchial asthma, treatment, genetic engineering therapy, omalizumab.

REFERENCES

1. Asiryan E.G. Kliniko-immunologicheskoe obosnovanie primenenie immunokorrigiruyushchego lecheniya u detey s bronkhial’noy astmoy [Clinical and immunological substantiation of the use of immunocorrective treatment in children with bronchial asthma]. Vitebsk: VGMU, 2018. 243 p.
2. Astaf’eva N.G., Gamova I.V., Udovichenko E.N., Perfilova I.A., Mikhaylova I.E., Naumova O.S. Clinical phenotypes of bronchial asthma in adolescents: difficulties in diagnosis and therapy. Lechashchiy vrach, 2015, no. 4, pp. 20–23 (in Russ.).
3. Sokolova L.V., Tsyplenkova S.E., Sorokina L.V., Mizernitskiy Yu.L. Experience of long-term use of omalizumab in children with severe bronchial asthma. Zemskiy vrach, 2011, no. 5 (9), pp. 21–24 (in Russ.).
4. Nenasheva N.M. Biological therapy of severe asthma: new goals and new treatment options. Meditsinskiy sovet, 2019, no. 15, pp. 50–61 (in Russ.).
5. Dobrynina E.A., Namazova-Baranova L.S., Vishneva E.A., Alekseeva A.A., Vinyarskaya I.V. Dynamics of the quality of life of patients with severe bronchial asthma during treatment with omalizumab. Pediatriya, 2017, no. 2 (96), pp. 33-40 (in Russ.).
6. Kurbacheva O.M., Galitskaya M.A. The place of omalizumab in the treatment of allergic diseases. Meditsinskiy sovet, 2019, no. 15, pp. 38-49 (in Russ.).
7. Deschildre A., Marguet C., Salleron J., Pin I., Rittié JL., Derelle J. et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir, 2013, vol. 42, rr. 1224–1233.